- Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of

MONTREAL and CHARLOTTE, N.C. , July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a securities purchase agreement

MONTREAL and CHARLOTTE, N.C. , May 27, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive

MONTREAL and CHARLOTTE, N.C. , May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020

–  Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – –  Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02), consistent with its known pharmacology – –  Study demonstrated a positive safety

– Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –   MONTREAL and CHARLOTTE, N.C. , March 6, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of